赞比亚母婴腺病毒中和抗体纵向定量:HIV-1感染及治疗的影响
研究在赞比亚67对母婴中定量了针对7种腺病毒(Ad4、5、7、26、28、45、48)的中和抗体,首次描述母婴转移抗体衰减动力学及婴儿de novo应答。母体HIV-1感染状态及抗逆转录病毒治疗(ART)多数情况下不影响母体腺病毒中和抗体水平及其向婴儿的转移。婴儿母体腺病毒中和抗体在12月龄降至最低点,提示七种腺病毒均可作为疫苗载体。
要点
- 赞比亚成人对7种腺病毒均有强中和抗体应答并有效转移至新生儿。
- 母体HIV-1感染及ART治疗多数情况下不影响腺病毒中和抗体水平及转移。
- 婴儿母体腺病毒中和抗体在12月龄降至最低点,为疫苗载体应用提供窗口。
核心结论
- 在赞比亚母婴对中,针对Ad4、Ad5、Ad7、Ad26、Ad28、Ad45和Ad48的中和抗体普遍存在并有效转移至新生儿,母体HIV-1感染及ART多数不影响该抗体水平及转移,婴儿母体抗体在12月龄降至最低点。
研究设计与样本
- 研究对67名赞比亚成年女性及其婴儿进行了纵向定量,检测针对Ad4、Ad5、Ad7、Ad26、Ad28、Ad45和Ad48的中和抗体,并分析母体HIV-1感染状态及ART治疗的影响。
主要发现
- 赞比亚成人对检测的每种腺病毒均存在强中和抗体应答,并有效转移至新生儿。
- 除少数例外,母体HIV-1感染状态或HIV-1疾病的ART治疗对母体腺病毒中和抗体应答及其向婴儿的转移无显著影响。
- 婴儿母体腺病毒中和抗体衰减至12月龄时达到最低点,此时七种腺病毒均可作为疫苗载体。
临床怎么用
- 本研究定义的12月龄抗体最低点窗口为在赞比亚等撒哈拉以南非洲地区合理设计和实施腺病毒载体疫苗提供了基础数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination offers the most cost-effective approach to limiting the adverse impact of infectious and neoplastic diseases that reduce the quality of life in sub-Saharan Africa (SSA). However, it is unclear what vaccine vectors would be most readily implementable in the setting and at what age they should be applied for maximal efficacy. Adenoviruses (Ad) and Ad-based vectors have been demonstrated to induce effective humoral and cellular immune responses in animal models and in humans. However, because immunity associated with Ad infection is lifelong, there exists a debate as to whether pre-existing immunity might decrease the efficacy of Ad vectored vaccines. In order to begin to rationally develop vaccination strategies for SSA, we have quantified neutralizing antibodies (nAb) against Ad4, Ad5, Ad7, Ad26, Ad28, Ad45 and Ad48 in 67 adult women and their infants. We are the first to define the decay kinetics of transferred maternal nAb in infants as well as the apparent initiation of de novo Ad responses. Our findings demonstrate that in Zambian adults, robust nAb responses exist against each of the Ads tested and are efficiently transferred to newborns. With few exceptions, neither the HIV-1 infection status of the mothers or the antiretroviral therapy (ART) treatment of HIV-1 disease had significant impact on maternal Ad nAb responses or their transfer to infants. However, maternal Ad nAb decays in infants to a nadir at 12 months of age such that any of the seven Ad types could function as vaccine vectors. The definition of this 'window of opportunity' provides important foundational data for rational design and implementation of Ad vectors in this setting.
引用
- Privatt SR, Bullard BL, Weaver EA, et al. Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment. Vaccine. 2019. PMID: 31378535. doi:10.1016/j.vaccine.2019.07.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。